GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unity Biotechnology Inc (NAS:UBX) » Definitions » Owner Earnings per Share (TTM)

Unity Biotechnology (Unity Biotechnology) Owner Earnings per Share (TTM) : -2.10 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Unity Biotechnology Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Unity Biotechnology's Owner Earnings per Share (TTM) ended in Mar. 2024 was $-2.10. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Unity Biotechnology's Owner Earnings per Share (TTM) or its related term are showing as below:



UBX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.745
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Unity Biotechnology's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.34. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.28. It's PE Ratio ratio for today is At Loss.

Unity Biotechnology's EPS without NRI for the three months ended in Mar. 2024 was $-0.42. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.37. It's PE Ratio without NRI ratio for today is At Loss.


Unity Biotechnology Owner Earnings per Share (TTM) Historical Data

The historical data trend for Unity Biotechnology's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unity Biotechnology Owner Earnings per Share (TTM) Chart

Unity Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial - - -10.13 -3.12 -2.43

Unity Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.42 -2.14 -2.26 -2.43 -2.10

Competitive Comparison of Unity Biotechnology's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, Unity Biotechnology's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unity Biotechnology's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unity Biotechnology's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Unity Biotechnology's Price-to-Owner-Earnings falls into.



Unity Biotechnology Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Unity Biotechnology's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -34.78
Depreciation, Depletion and Amortization 1.08
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 0.81
Change In Working Capital -0.79
Shares Outstanding (Diluted Average) 16.79

1. Start with "Net Income" from income statement. Unity Biotechnology's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-34.78 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Unity Biotechnology's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2024 was $1.08 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Unity Biotechnology's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.81 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Unity Biotechnology's 5-Year Average Maintenance Capital Expenditure = $0.81 Mil

5. "Change In Working Capital" is from cashflow statement. Unity Biotechnology's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.79 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Unity Biotechnology's Shares Outstanding (Diluted Average) for the months ended in Mar. 2024 was 16.785 Mil.

Unity Biotechnology's Onwer Earnings Per Share for Mar. 2024 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -34.782 +1.08+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.80727272727273+-0.791)/16.785
=-2.10

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=1.60/-2.10
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Unity Biotechnology Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Unity Biotechnology's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Unity Biotechnology (Unity Biotechnology) Business Description

Traded in Other Exchanges
Address
285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases.
Executives
Anirvan Ghosh director, officer: Chief Executive Officer C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jamie Dananberg officer: Chief Medical Officer 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael P. Samar director C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST. SUITE 310, CARMEL IN 46032
Alexander Hieu Nguyen officer: See Remarks C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Nathaniel E David director, officer: President C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Gilmore Neil O'neill director 215 FIRST STREET, CAMBRIDGE MA 02142
Alexander Azoy officer: See Remarks 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Lynne Marie Sullivan officer: See Remarks C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Robert Nelsen director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Graham K Cooper director C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Paul L Berns director 11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020
Camille D Samuels director 2463 JACKSON ST., SAN FRANCISCO CA 94115
Kristina Burow director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David L. Lacey director 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Dan Marquess officer: Chief Scientific Officer 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005

Unity Biotechnology (Unity Biotechnology) Headlines